Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Wouldn't you Love to see a repeat of some old PRs

2-14-06 – Press release announcing $.02 dividend

3-0-06- Press release announcing 2nd dividend, this one was $.04.The company has been advised that it will likely receive the distribution of its share of the proceeds from the recently announced patent portfolio license transactions by the end of March

4-5-06- Press release, Patriot received share of proceeds from licensing agreement with Fujitsu.Revenue from distributions will fund unprecedented 2nd dividend to be paid April 24

4-24-06 – Press release, PTSC today announces plan under which it would utilize 10% or more of future licensing revenues to buy back corporate stock on the open market

2-22-07- Press release, PTSC announces dividend of $.02 (that was number 3)

6-18-07 Press release, TPL & PTSC applauded the Markman ruling in the Eastern District of Texas.While the ruling confirms MMP Portfolio claims against Matsushita, Panasonic, JVC, Toshiba and NEC entities, there remains a specific, highly technical phase that will require further scrutiny.

Not sure what was meant by the highly technical phase (above). Did this phase result in the non disclosure of facts relating to the settlement agreement with the J3? Should we expect another highly technical phase that will require further scrutiny with the pending Markman, should it (Markman) be favorable.

Share
New Message
Please login to post a reply